Singapore Health Sciences Authority Cracks Down on E-Cigarette Black Market

Jul.05.2024
Singapore Health Sciences Authority Cracks Down on E-Cigarette Black Market
Singapore Health Sciences Authority (HSA) seized over 350,000 e-cigarette products worth $6 million in June raids.

According to Channel News Asia's report on July 4th, the Health Sciences Authority (HSA) in Singapore stated that over 350,000 e-cigarette products were seized in raids across the country in June.


The black market value of these e-cigarette products exceeds 6 million Singapore dollars (approximately 4.44 million US dollars) and were originally planned to be sold through Telegram.


The Health Sciences Authority (HSA) confirmed that a series of raids carried out from June 14 to 18 at three separate locations effectively targeted one of Singapore's largest e-cigarette distribution networks.


Authorities received news on June 14 that a large quantity of e-cigarettes and components were found in a warehouse at Woodlands Loop.


Following that, there were two more raids conducted, one at an apartment unit on Guillemard Crescent on the same day, and another at a warehouse unit in the Woodlands industrial park on June 18th. HSA stated that more e-cigarette products were also found at these two locations.


Additionally, 14 e-cigarettes suspected to contain the controlled substance tetrahydrocannabinol (THC) have been discovered, and these products have been handed over to the Central Narcotics Bureau (CNB) for processing. Four men and women, ranging in age from 34 to 52, are currently assisting in the investigations conducted by the Health Sciences Authority (HSA) and CNB.


The Health Sciences Authority (HSA) has reported seizures of e-cigarette products worth over 18 million Singapore dollars (13.32 million US dollars) since January. Authorities have warned that importing, distributing, selling, or advertising e-cigarette products is illegal.


For the first time offenders found importing, distributing, or selling e-cigarette products, they can be fined up to $10,000 (USD 7401), or face imprisonment for a maximum of 6 months, or both. For second-time offenders and beyond, the maximum fine can reach $20,000 (USD 14,802), or imprisonment for up to 12 months, or both. It is illegal to purchase, use, or possess e-cigarettes, with a maximum fine of $2000 (USD 1480).


Last year, Singapore authorities dealt with around 8,000 cases of e-cigarette-related offenses, a 43% increase from the 5,600 cases in 2022. There were a total of 7,600 recorded offenses in 2021.


In December of last year, authorities announced plans to enhance inspections of e-cigarettes and their components at border checkpoints in Singapore. They also stated that they would increase efforts to combat the use of e-cigarettes in "public hotspots.


From January 1 to March 31, it was discovered that over 2200 people were using or in possession of e-cigarettes.


In May this year, Rahayu Mahzam, the Senior Parliamentary Secretary of the Ministry of Health, stated that the Health Sciences Authority is reviewing legal penalties to enhance deterrence against e-cigarette advertising, importation, and distribution.


She added that the Health and Safety Authority has been monitoring illegal e-cigarette sales on social media, e-commerce, and communication platforms, and taking action to remove e-cigarette-related content.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Jinjia Venture Faces New Judicial Auction, Control Unchanged
Jinjia Venture Faces New Judicial Auction, Control Unchanged
Jinjia Group said its controlling shareholder, Jinjia Venture, will have part of its holdings auctioned by the Shenzhen Nanshan Court, involving 43.4 million shares. Earlier, the Shenzhen Intermediate Court announced another auction of 37.27 million shares. Together they represent 5.56% of total equity. Jinjia said the auctions will not affect company control.
Oct.23 by 2FIRSTS.ai
Philip Morris Korea Launches New TEREA Packaging for IQOS ILUMA to Mark Third Anniversary
Philip Morris Korea Launches New TEREA Packaging for IQOS ILUMA to Mark Third Anniversary
Philip Morris Korea has announced a new packaging design for TEREA, the dedicated tobacco stick brand for its heat-not-burn device IQOS ILUMA, to celebrate the third anniversary of its launch in South Korea. The newly designed products are now available at nine IQOS flagship stores and major convenience stores across the country.
Nov.13 by 2FIRSTS.ai
South Korea Implements Public Tobacco Harmfulness Management Program, Including 22 Harmful Components in E-Cigarettes
South Korea Implements Public Tobacco Harmfulness Management Program, Including 22 Harmful Components in E-Cigarettes
South Korea’s Ministry of Health and Welfare and the Ministry of Food and Drug Safety convened the first 2025 Tobacco Harmfulness Management Policy Committee, finalizing new lists of harmful substances for cigarettes, heated tobacco products, and liquid e-cigarettes to be publicly disclosed from next year.
Nov.14 by 2FIRSTS.ai
SKE’s Parent Company Yinghe Technology Reports 80% Drop in Q3 Net Profit, Revenue Up 22.85% Year-on-Year
SKE’s Parent Company Yinghe Technology Reports 80% Drop in Q3 Net Profit, Revenue Up 22.85% Year-on-Year
Yinghe Technology (SZ: 300457), parent company of SKE, saw Q3 net profit plunge 80.3% to 31.06 million yuan, while revenue rose 22.85% to 2.52 billion yuan. The decline was mainly driven by higher costs and expenses.
Oct.28 by 2FIRSTS.ai
1,200 Health Leaders Urge UK Parliament to Pass Tobacco and Vapes Bill Swiftly
1,200 Health Leaders Urge UK Parliament to Pass Tobacco and Vapes Bill Swiftly
Over 1,200 UK health leaders urged Parliament to pass the Tobacco and Vapes Bill quickly, calling it vital to protect future generations. The bill would ban tobacco sales to anyone born after Jan 1, 2009, and restrict vape packaging and flavours. Health groups warned delays risk undermining “gamechanging” public health reforms.
Oct.27 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai